secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064475
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025
--------------------------------------------------------------------------------

- Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.
- Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.
- Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.
- Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.
- R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/0000950170-25-064475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/lyra-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer